Lions & Lambs in the Device & DX Industries
Do big companies differ from small companies only in the size of their resource pool? The different, if not imcompatible perspectives of big and small companies was a recurring theme of the formal sessions and informal discussions at Phoenix '96, a conference for CEOs of medical device and diagnostics companies.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.